Form 8-K OCULAR THERAPEUTIX, INC For: May 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c; Sees DEXTENZA NDA Submission in H215
May 15, 2015 6:47 AM EDTOcular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.35), $0.04 better than the analyst estimate of ($0.39).
Clinical Update for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain
Following a Pre-NDA Clinical meeting held with FDA in April 2015, Ocular Therapeutix is charting... More
